CDAKQ Codiak Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CDAKQ

Price (delayed)

$0.0016

Market cap

$58,927

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$5.4M

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum ...

Highlights
The gross profit has soared by 102% YoY
CDAKQ's revenue has soared by 102% year-on-year
The company's EPS has shrunk by 107% YoY but it rose by 24% QoQ
CDAKQ's equity is up by 14% year-on-year but it is down by 12% since the previous quarter
The quick ratio is down by 9% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.codiakbio.com

Key stats

What are the main financial stats of CDAKQ
Market
Shares outstanding
36.83M
Market cap
$58,927
Enterprise value
$5.4M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0
Price to sales (P/S)
0
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.16
Earnings
Revenue
$34.07M
EBIT
-$14.81M
EBITDA
-$10.49M
Free cash flow
-$67.77M
Per share
EPS
-$0.64
Free cash flow per share
-$2.69
Book value per share
$1.72
Revenue per share
$1.35
TBVPS
$5.34
Balance sheet
Total assets
$134.4M
Total liabilities
$95.47M
Debt
$61.28M
Equity
$38.93M
Working capital
$46.78M
Liquidity
Debt to equity
1.57
Current ratio
4.24
Quick ratio
3.87
Net debt/EBITDA
-0.51
Margins
EBITDA margin
-30.8%
Gross margin
100%
Net margin
-51.1%
Operating margin
-143.2%
Efficiency
Return on assets
-11.8%
Return on equity
-37.6%
Return on invested capital
-11.2%
Return on capital employed
-12.3%
Return on sales
-43.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CDAKQ stock price

How has the Codiak Biosciences stock price performed over time
Intraday
-81.18%
1 week
-64.44%
1 month
-86.89%
1 year
-99.94%
YTD
-99.6%
QTD
-80.95%

Financial performance

How have Codiak Biosciences's revenue and profit performed over time
Revenue
$34.07M
Gross profit
$34.07M
Operating income
-$48.8M
Net income
-$17.42M
Gross margin
100%
Net margin
-51.1%
The gross profit has soared by 102% YoY
CDAKQ's revenue has soared by 102% year-on-year
Codiak Biosciences's net margin has soared by 88% YoY and by 11% from the previous quarter
The company's net income has surged by 76% YoY and by 12% QoQ

Growth

What is Codiak Biosciences's growth rate over time

Valuation

What is Codiak Biosciences stock price valuation
P/E
N/A
P/B
0
P/S
0
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.16
The company's EPS has shrunk by 107% YoY but it rose by 24% QoQ
The P/B is 100% less than the last 4 quarters average of 2.4
CDAKQ's equity is up by 14% year-on-year but it is down by 12% since the previous quarter
CDAKQ's revenue has soared by 102% year-on-year
CDAKQ's price to sales (P/S) is 100% less than its last 4 quarters average of 4.8

Efficiency

How efficient is Codiak Biosciences business performance
The company's return on sales has surged by 89% YoY and by 13% QoQ
Codiak Biosciences's ROIC has soared by 83% YoY and by 19% from the previous quarter
The ROE has soared by 78% year-on-year and by 15% since the previous quarter
The ROA has soared by 72% year-on-year and by 9% since the previous quarter

Dividends

What is CDAKQ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CDAKQ.

Financial health

How did Codiak Biosciences financials performed over time
The total assets is 41% greater than the total liabilities
Codiak Biosciences's total liabilities has decreased by 23% YoY but it has increased by 8% QoQ
The total assets has declined by 15% year-on-year
Codiak Biosciences's debt is 57% more than its equity
The company's debt to equity fell by 15% YoY but it rose by 13% QoQ
CDAKQ's equity is up by 14% year-on-year but it is down by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.